LLBH Private Wealth Management LLC purchased a new position in Urogen Pharma (NASDAQ:URGN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 38,461 shares of the company’s stock, valued at approximately $695,000.

Separately, Spark Investment Management LLC purchased a new stake in shares of Urogen Pharma during the second quarter worth $856,000. Hedge funds and other institutional investors own 3.59% of the company’s stock.

Urogen Pharma (NASDAQ:URGN) opened at 18.42 on Tuesday. The company’s 50-day moving average is $18.06 and its 200-day moving average is $17.58. Urogen Pharma has a 52-week low of $13.01 and a 52-week high of $20.02. The firm’s market capitalization is $42.46 million.

COPYRIGHT VIOLATION NOTICE: This article was published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/38461-shares-in-urogen-pharma-urgn-acquired-by-llbh-private-wealth-management-llc/1491356.html.

A number of equities analysts recently issued reports on the stock. Oppenheimer Holdings, Inc. set a $32.00 price objective on shares of Urogen Pharma and gave the stock a “buy” rating in a research report on Monday. Zacks Investment Research upgraded shares of Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Wednesday, August 2nd. Raymond James Financial, Inc. assumed coverage on shares of Urogen Pharma in a research report on Tuesday, May 30th. They set an “outperform” rating and a $25.00 price objective for the company. Jefferies Group LLC assumed coverage on shares of Urogen Pharma in a research report on Tuesday, May 30th. They set a “buy” rating and a $27.00 price objective for the company. Finally, Cowen and Company assumed coverage on shares of Urogen Pharma in a research report on Tuesday, May 30th. They set an “outperform” rating for the company. Five research analysts have rated the stock with a buy rating, Urogen Pharma has an average rating of “Buy” and a consensus price target of $26.00.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urogen Pharma (NASDAQ:URGN).

Institutional Ownership by Quarter for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.